Jeffrey Casberg discusses key upcoming biosimilars and specialty drugs, the impact of the Inflation Reduction Act on drug pricing, and the evolving role of pharmacy benefit managers in the market.

For lecanemab, scientists at AAIC highlighted the promise of the fluid tau marker MTBR-243 to track tangle load, and they ...

Modeling suggests monthly maintenance dosing will keep biomarkers flat. Several talks showed how fluid biomarkers rebound after patients stop taking the drug. Likewise, cognitive decline returned to ...

Alzheimer’s drug, donanemab (marketed as Kisunla), could be rejected for use by the National Health Service (NHS) in Britain, ...

Donanemab - hailed by scientists as the 'best ever' treatment for the disease - has been shown in trials to slow cognitive ...

The Alzheimer's drug Donanemab is expected to face a block for its use within the NHS, according to a report by The Telegraph. This marks the second time such a drug has faced obstacles within the UK ...

Eli Lilly and Company's (LLY) tirzepatide (Mounjaro/Zepbound) continues to produce commercial and clinical wins. After a stellar second quarter earnings report and a $3 billion revenue guidance ...

Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297 Technology appraisal guidance TBC Datopotamab deruxtecan for previously treated ...

Major trials have found that the drugs lecanemab and donanemab slow down the early stages of Alzheimer’s disease – which is the most common form of dementia. However, their effectiveness ...

Lilly's donanemab sails through FDA meeting with 2 unanimous votes in favor Behind Kisunla, Lilly has remternetug in phase 3 development, which targets amyloid plaques in the brain.

Lecanemab and donanemab, are the most recent medicines to enter the market to treat Alzheimer's, a disease which is more prevalent in older people. With populations increasingly aging, there is a huge ...

The drugs, lecanemab and donanemab, work by clearing out amyloid in the brain. Amyloid is the protein that aggregates on neurons and stops the brain working properly, causing dementia. Both the ...